Polysomnography Study of GSK1838262 (XP13512) Extended Release Tablets Versus Placebo in Restless Legs Syndrome (RLS) and Associated Sleep Disturbance - Full Text View

Sponsored by:	GlaxoSmithKline
Information provided by:	GlaxoSmithKline
ClinicalTrials.gov Identifier:	NCT00748098

Purpose

The purpose of this study is to assess the efficacy and safety of GSK1838262 extended release tablets in the treatment of patients with Restless Legs Syndrome and associated sleep disturbance.

Condition	Intervention	Phase
Restless Legs Syndrome (RLS)	Drug: GSK1838262 Extended Release Tablets Drug: Placebo	Phase III

MedlinePlus related topics: Restless Legs Sleep Disorders

Drug Information available for: Gabapentin

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Crossover Assignment, Safety/Efficacy Study
Official Title:	Study RXP110908, a Polysomnography Study of GSK1838262 (XP13512) Extended Release Tablets Versus Placebo in the Treatment of Restless Legs Syndrome (RLS) and Associated Sleep Disturbance

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:

Change from baseline to end of each treatment period in Wake Time During Sleep (WTDS) measured by polysomnography [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Change from baseline to end of each treatment period in Periodic Limb Movements associated with Arousal per hour (PLMAI) measured by polysomnography [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
Assess safety, tolerability, polysomnography efficacy measures, and patient reported outcomes. [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment:	114
Study Start Date:	October 2008
Estimated Study Completion Date:	June 2009
Estimated Primary Completion Date:	June 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
GSK1838262:placebo GSK1838262 extended release tablets for Treatment Period 1 followed by Placebo for Treatment Period 2	Drug: GSK1838262 Extended Release Tablets GSK1838262 extended release tablets Drug: Placebo Placebo
Placebo:GSK1838262 Placebo for Treatment Period 1 followed by GSK1838262 for Treatment Period 2	Drug: GSK1838262 Extended Release Tablets GSK1838262 extended release tablets Drug: Placebo Placebo

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion criteria:

Provided written informed consent.
Diagnosed with primary RLS using the International RLS Study Group Diagnostic Criteria with a total score of 15 or greater on the International RLS (IRLS) Rating Scale and significant sleep disturbance indicated on Item 4 of the IRLS rating scale.
Have history of RLS symptoms at least 15 nights/month.
Minimum average of 15 Periodic Limb Movements during Sleep per hour (measured using actigraphy).

Exclusion criteria:

Secondary RLS
Primary sleep disorder
Sleep apnea
Have any medical conditions that may impact efficacy assessments or that may present a safety concern.
Pregnant or lactating or women of child-bearing potential who are not practicing an acceptable method of birth control.
Use of any prohibited medication.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00748098

Contacts

Contact: US GSK Clinical Trials Call Center

877-379-3718

Show 39 Study Locations

Sponsors and Collaborators

GlaxoSmithKline

Investigators

Study Director:

GSK Clinical Trials

GlaxoSmithKline

More Information

study website This link exits the ClinicalTrials.gov site

Responsible Party:	GSK ( Study Director )
Study ID Numbers:	RXP110908
Study First Received:	September 5, 2008
Last Updated:	January 8, 2009
ClinicalTrials.gov Identifier:	NCT00748098
Health Authority:	United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:

Restless Legs Syndrome
RLS
GSK1838262
XP13512

polysomnography
PSG
sleep disturbance
gabapentin enacarbil

Study placed in the following topic categories:

Excitatory Amino Acids
Ekbom syndrome
Gabapentin
Sleep Disorders
Dyssomnias
Psychomotor Agitation
Dyskinesias

Sleep Disorders, Intrinsic
Signs and Symptoms
Calcium, Dietary
Mental Disorders
Restless Legs Syndrome
Neurologic Manifestations
Neurobehavioral Manifestations

Additional relevant MeSH terms:

Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anti-Dyskinesia Agents
Physiological Effects of Drugs
Psychotropic Drugs
Antiparkinson Agents
Calcium Channel Blockers
Excitatory Amino Acid Agents
Membrane Transport Modulators
Pathologic Processes
Sensory System Agents
Therapeutic Uses
Syndrome
Psychomotor Disorders

Analgesics
Excitatory Amino Acid Antagonists
Disease
Tranquilizing Agents
Parasomnias
Nervous System Diseases
Central Nervous System Depressants
Cardiovascular Agents
Antimanic Agents
Pharmacologic Actions
Anti-Anxiety Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Anticonvulsants

ClinicalTrials.gov processed this record on January 14, 2009